Sage Therapeutics
During the J.P. Morgan Healthcare Conference, Sage provided an update on its long-term strategy to drive growth at the company.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
Shares of Sage have shot up more than 75 percent this morning as a result of the impressive data.
Sage Therapeutics has been on a roll with good news lately.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
The positive results support the company’s planned regulatory submissions.
JOBS
IN THE PRESS